Good explaination. When GC was talking about this last Fall, it sounded like they saved AMBS a lot of headaches and money. I remember when the company was trying to push Lympro forward, the goal posts would keep moving along with the definition of what is good enough.

That is the downside of going first and why a lot of other people follow. You'll always hear the argument first to the finish line wins but if that was the case, there would be only one product for each time of illness and disease. The reality is, even the first to market doesn't work for everyone or has side effects that people can't tolerate.